Harvard Bioscience Inc (HBIO)

Currency in USD
0.721
-0.033(-4.37%)
Closed·
0.720-0.001(-0.08%)
·
HBIO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.7130.770
52 wk Range
0.2812.280
Key Statistics
Prev. Close
0.754
Open
0.765
Day's Range
0.713-0.77
52 wk Range
0.281-2.28
Volume
364.34K
Average Volume (3m)
6.36M
1-Year Change
-65.67%
Book Value / Share
0.32
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HBIO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2.000
Upside
+177.39%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Harvard Bioscience Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Harvard Bioscience Company Profile

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Harvard Bioscience Inc Earnings Call Summary for Q3/2025

  • Harvard Bioscience Q3 2025 reported EPS of -$0.03 (400% below forecast), while revenue reached $20.6 million (8.42% above expectations), causing a 2.77% premarket stock decline
  • Gross margin improved to 58.4% from 58.1% year-over-year, with adjusted EBITDA rising to $2 million from $1.3 million in Q3 2024
  • The company reduced net debt by over $6 million to $27.5 million and reported strong cash flow from operations despite regional challenges in China/APAC
  • Management provided Q4 2025 revenue guidance of $22.5-24.5 million with gross margins between 58-60%, noting potential impacts from a U.S. government shutdown affecting NIH funding
  • CEO John Duke stated the company is 'fundamentally stronger today than it was to start the year: leaner, more focused, and better aligned with long-term growth opportunities'
Last Updated: 06/11/2025, 13:50
Read Full Transcript

Compare HBIO to Peers and Sector

Metrics to compare
HBIO
Peers
Sector
Relationship
P/E Ratio
−0.6x32.3x−0.6x
PEG Ratio
0.000.140.00
Price/Book
2.3x1.2x2.6x
Price / LTM Sales
0.4x3.0x3.2x
Upside (Analyst Target)
177.4%168.2%41.8%
Fair Value Upside
Unlock8.2%5.1%Unlock

Analyst Ratings

1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 2.000
(+177.39% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Benchmark
Buy2.00+177.39%3.00Maintain10/09/2025
Benchmark
Buy3.00+316.09%3.00Maintain18/07/2025
Benchmark
Buy3.00+316.09%4.50Maintain13/05/2025
Benchmark
Buy4.50+524.13%4.50Maintain14/04/2025
KeyBanc
Hold---Downgrade09/04/2025

Earnings

Latest Release
Nov 06, 2025
EPS / Forecast
-0.03 / 0.01
Revenue / Forecast
20.60M / 19.00M
EPS Revisions
Last 90 days

People Also Watch

0.580
SCNX
+11.12%
2.430
CMND
-6.18%
1.27
RUBI
-9.29%
0.047
VIVK
-24.39%
0.46
VSEE
+4.49%

FAQ

What Is the Harvard Bioscience (HBIO) Share Price Today?

The live Harvard Bioscience share price today is 0.721

What Stock Exchange Does Harvard Bioscience (HBIO) Trade On?

Harvard Bioscience is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Harvard Bioscience?

The stock symbol (also called a 'ticker') for Harvard Bioscience is "HBIO."

What Is the Current Harvard Bioscience Market Cap?

As of today, Harvard Bioscience market capitalisation is 32.13M.

What Is Harvard Bioscience's (HBIO) Earnings Per Share (TTM)?

The Harvard Bioscience EPS is currently -1.22 (Trailing Twelve Months).

When Is the Next Harvard Bioscience Earnings Date?

Harvard Bioscience's next earnings report will be released on 05 Mar 2026.

Is HBIO a Buy or Sell From a Technical Analyst Perspective?

Based on today's Harvard Bioscience moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Harvard Bioscience Stock Split?

Harvard Bioscience has split 0 times. (See the HBIO stock split history page for full effective split date and price information.)

How Many Employees Does Harvard Bioscience Have?

Harvard Bioscience has 343 employees.

What is the current trading status of Harvard Bioscience (HBIO)?

As of 24 Dec 2025, Harvard Bioscience (HBIO) is trading at a price of 0.721, with a previous close of 0.754. The stock has fluctuated within a day range of 0.713 to 0.770, while its 52-week range spans from 0.281 to 2.280.

What Is Harvard Bioscience (HBIO) Price Target According to Analysts?

The average 12-month price target for Harvard Bioscience is USD2, with a high estimate of USD2 and a low estimate of USD2. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +177.39% Upside potential.

What Is the HBIO Premarket Price?

HBIO's last pre-market stock price is 0.775. The pre-market share volume is 3,960.000, and the stock has decreased by 0.021, or 2.790%.

What Is the HBIO After Hours Price?

HBIO's last after hours stock price is 0.720, the stock has decreased by -0.001, or -0.080%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.